The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Trapping Channel Block of NMDA-Activated Responses By Amantadine and Memantine
Abstract
Blanpied, Thomas A., Faye Boeckman, Elias Aizenman, and Jon W. Johnson. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77: 309–323, 1997. We investigated the mechanisms by which the antiparkinsonian and neuroprotective agents amantadine and memantine inhibit responses to N-methyl-d-aspartic acid (NMDA). Whole cell recordings were performed using cultured rat cortical neurons or Chinese hamster ovary (CHO) cells expressing NMDA receptors. Both amantadine and memantine blocked NMDA-activated channels by binding to a site at which they could be trapped after channel closure and agonist unbinding. For neuronal receptors, the IC 50 s of amantadine and memantine at −67 mV were 39 and 1.4 μM, respectively. When memantine and agonists were washed off after steady-state block, one-sixth of the blocked channels released rather than trapped the blocker; memantine exhibited “partial trapping.” Thus memantine appears to have a lesser tendency to be trapped than do phencyclidine or (5R,10S)-(+)-5m e t h y l - 1 0 , 1 1 - d i h y d r o - 5 H - d i b e n z o [ 1 , d ] c y c l i h e p t e n - 5 , 1 0 - i m i n e(MK-801). We next investigated mechanisms that might underlie partial trapping. Memantine blocked and could be trapped by recombinant NMDA receptors composed of NR1 and either NR2A or NR2B subunits. In these receptors, as in the native receptors, the drug was released from one-sixth of blocked channels rather than being trapped in all of them. The partial trapping we observed therefore was not due to variability in the action of memantine on a heterogeneous population of NMDA receptors in cultured cortical neurons. Amantadine and memantine each noncompetitively inhibited NMDA-activated responses by binding at a second site with roughly 100-fold lower affinity, but this form of inhibition had little effect on the extent to which memantine was trapped. A simple kinetic model of blocker action was used to demonstrate that partial trapping can result if the presence of memantine in the channel affects the gating transitions or agonist affinity of the NMDA receptor. Partial trapping guarantees that during synaptic communication in the presence of blocker, some channels will release the blocker between synaptic responses. The extent to which amantadine and memantine become trapped after channel block thus may influence their therapeutic effects and their modulation of NMDA-receptor-mediated excitatory postsynaptic potentials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green fluorescent protein as a marker for gene expression
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., & Prasher, D. C. (1994) · Science · doi:10.1126/science.8303295 · Cited by 6,802 · cited 5×
“The expression vector containing NR2B was created by ligating the 5.4-kb EcoRI fragment of pNR2B (Monyer et al. 1992) The array of tubes was mounted on a linear ball slide assembly (DelTron Precision, Bethel, CT) and moved by a D.C. linear motorinto a partial EcoRI digest of pRc/CMV. Green fluorescent protein (GFP) (C…”
MethodInfluentialKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Huettner, J. E., & Bean, B. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1307 · Cited by 751
Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine
MacDonald, J. F., Miljkovic, Z., & Pennefather, P. (1987) · Journal of Neurophysiology · doi:10.1152/jn.1987.58.2.251 · Cited by 387
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
“Channel block by trapping blockers is slow to reverse and requires channel reactivation by agonists before the blocker can dissociate (Brackley et al., 1993; Parsons et al., 1995; Blanpied et al., 1997; Magazanik et al., 1997).”
BackgroundThe Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
“The apparently favorable outlook for the use of memantine in the treatment 24 DINGLEDINE ET AL. of neurological diseases may reflect its partial trapping in closed NMDA channels (Blanpied et al., 1997).”
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
Ligands for Glutamate Receptors: Design and Therapeutic Prospects
Bräuner-Osborne, H., Egebjerg, J., Nielsen, E. Ø., Madsen, U., & Krogsgaard-Larsen, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000007r · Cited by 524
Mechanism of action of memantine
JOHNSON, J., & KOTERMANSKI, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 502
Self-citationThe chemical biology of clinically tolerated NMDA receptor antagonists
Chen, H. V., & Lipton, S. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03991.x · Cited by 474
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Mg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
Self-citationTherapeutics of Neurotransmitters in Alzheimer’s Disease
Kandimalla, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161118 · Cited by 268
Targeting the N-Methyl-d-Aspartate Receptor for Chronic Pain Management
Fisher, K., Coderre, T. J., & Hagen, N. A. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00213-x · Cited by 266
Lipton, S. A. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6s610 · Cited by 194
Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block
Dravid, S. M., Erreger, K., Yuan, H., Nicholson, K., Le, P., Lyuboslavsky, P., Almonte, A., Murray, E., Mosley, C., Barber, J., et al. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.124958 · Cited by 184
Fedele, L., Newcombe, J., Topf, M., Gibb, A., Harvey, R. J., & Smart, T. G. (2018) · Nature Communications · doi:10.1038/s41467-018-02927-4 · Cited by 82
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
NMDA receptor antagonism: escalation of aggressive behavior in alcohol-drinking mice
Newman, E. L., Chu, A., Bahamón, B., Takahashi, A., DeBold, J. F., & Miczek, K. A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2734-9 · Cited by 46
“Memantine and neramexane are unique uncompetitive NMDAR antagonists with low receptor affinities, enabling ‘partial trapping’—a tendency to unblock some receptors between depolarizations (Blanpied et al. 1997; Kotermanski et al. 2009).”
Turcu, A. L., Companys-Alemany, J., Phillips, M. B., Patel, D. S., Griñán-Ferré, C., Loza, M. I., Brea, J. M., Pérez, B., Soto, D., Sureda, F. X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114354 · Cited by 27
Metadata
- Authors
- Blanpied, T. A., Boeckman, F. A., Aizenman, E., & Johnson, J. W.
- Venue
- Journal of Neurophysiology
- Publisher
- American Physiological Society
- Published
- 1997-01-01
- Volume
- 77
- Issue
- 1
- Pages
- 309-323
- ISSN
- 0022-3077 (ISSN-L)
- 1522-1598
- OpenAlex
- W1932992301
- Cited by
- 249
- References
- 5
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.